Er-Kim Secures Deal to Distribute KIMMTRAK in Turkey, MENA, Caucasus, and CIS Regions

Er-Kim, a well-established pharmaceutical company recognized for its focus on novel therapeutics, has expanded its distribution network through a strategic partnership with Immunocore. This collaboration is aimed at enhancing the availability of KIMMTRAK® (tebentafusp), a treatment specifically designed for HLA-A*02:01-positive adults suffering from unresectable or metastatic uveal melanoma. This agreement covers distribution in Turkey, the Middle East, North Africa, Caucasus, and the Commonwealth of Independent States (CIS).

Immunocore, a biotechnology firm listed on Nasdaq under the ticker IMCR, has been at the forefront of developing immunomodulating medicines that significantly improve health outcomes for patients battling cancer, infectious diseases, and autoimmune conditions. Uveal melanoma, the focus of this recent agreement, is a particularly aggressive and rare ocular cancer. Despite being the most prevalent form of primary intraocular malignancy in adults, uveal melanoma is still considered uncommon, and many patients ultimately develop metastatic disease. Historically, those diagnosed with unresectable or metastatic uveal melanoma have faced challenging prognoses.

Mert Zorlular, CFO of Er-Kim, expressed enthusiasm for the partnership with Immunocore, emphasizing the company's commitment to increasing access to essential treatments for eligible patients across the specified regions. Er-Kim boasts over four decades of experience in delivering innovative cancer therapies, solidifying its reputation as a trusted partner within the oncology community. Their efforts are primarily directed towards addressing diseases with significant unmet needs.

Founded in 1981, Er-Kim has established itself as a leader in biopharmaceutical innovation, collaborating with more than 40 global industry leaders to transform patient care in crucial international markets. Their business models have been expertly crafted to ensure sustainability and adaptability, thus positioning Er-Kim as a comprehensive service provider. The company's reach extends to more than 600 million patients through its fully owned affiliates. With a strong workforce of over 300 professionals globally and revenues surpassing EUR 305 million, Er-Kim is recognized not just as a partner but as an innovator in healthcare, consistently redefining standards in commercialization and patient access.

KIMMTRAK® (tebentafusp) has received approval in select countries as a monotherapy for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The availability and conditions for prescribing the treatment vary by country. Healthcare professionals in the United Kingdom can refer to the comprehensive Summary of Product Characteristics (SmPC) for detailed information about the product.

This strategic alliance between Er-Kim and Immunocore signifies a crucial step forward in the fight against uveal melanoma. By expanding access to KIMMTRAK® across numerous regions, Er-Kim is reinforcing its dedication to addressing critical healthcare challenges and supporting patients in need of advanced treatment options. The collaboration underscores the importance of global partnerships in advancing medical research and patient care, paving the way for improved treatments and outcomes in oncology.